WuXi Biologics and Prima Signs MOU and Announces Strategic Development and Manufacturing Partnership
SHANGHAI and SYDNEY, Nov. 23, 2016 — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Prima Biomed Ltd. (Prima), an ASX (PRR) and Nasdaq (PBMD) listed company developing IMP321, a recombinant soluble LAG-3 protein and other LAG-3 related products for use in oncology, announced today that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership.
Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima’s development partner in China, Eddingpharm. WuXi Biologics will also be Prima’s preferred partner to manufacture potential new products.
IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy is currently in Phase II trials in Europe.
CEO of Prima BioMed, Mr. Marc Voigt said, “Securing the future supply of IMP321 is a key component of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our strategic partnership.”
“We are honored to play a critical role to enable biotech and pharma companies to realize commercialization via WuXi’s innovative biomanufacturing network based on state-of-the-art disposable manufacturing technology,” said Dr. Chris Chen, CEO of WuXi Biologics, “WuXi Biologics is committed to producing the highest quality product to enable robust global supply of this potential biologics to patients worldwide.”